Posted inBiotechnology
Roche drops muscle-sparing obesity antibody after flunked interim analysis
Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in…
Posted inBiotechnology
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s…
Posted inBiotechnology
Scynexis bags $214M BARDA contract for antifungal development
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Scynexis with a $214 million contract for development of a treatment…
Posted inBiotechnology
Tolerance continues thymus-focused deals with $560M pact for Tanabe’s clinical-stage IL-33 drug
After vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused…
Posted inGenetics
Viral Protein Helps Self-Amplifying RNA Overcome Cellular Defenses
mRNA molecule, illustration. [Kateryna Kon/Science Photo Library/Getty Images] A new study led by scientists at Queen Mary University of London…
Posted inMedical Technology
Precision Neuroscience taps $250M in Series D funding for brain-computer interface
Precision Neurosciences, which specializes in brain-computer interface technology, raised $250 million in an oversubscribed Series D financing round.
Posted inBiotechnology
Kodiak’s stock doubles as resurrected eye disease drug matches Eylea in phase 3
Two of Kodiak Sciences’ drug candidates have matched Eylea in a phase 3 clinical trial, positioning the biotech to seek FDA…
Posted inBiotechnology
Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D
Merck & Co. has become the latest pharma to jump on the KRAS G12D bandwagon, paying $400 million to China’s…
Posted inMedical Technology
VC Sofinnova reels in €82M to target medtechs in the next 5 years
Sofinnova Partners has hauled in 82 million euro ($93.3 million) in an oversubscribed financing round. The European venture capital group…
Posted inBiotechnology
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Daiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data…